- Home
- IBRX vs PENN Comparison
IBRX vs PENN Comparison
Compare IBRX & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PENN
- Stock Information
- Founded
- IBRX 2014
- PENN 1972
- Country
- IBRX United States
- PENN United States
- Employees
- IBRX N/A
- PENN N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PENN Hotels/Resorts
- Sector
- IBRX Health Care
- PENN Consumer Discretionary
- Exchange
- IBRX Nasdaq
- PENN Nasdaq
- Market Cap
- IBRX 2.4B
- PENN 2.3B
- IPO Year
- IBRX N/A
- PENN 1994
- Fundamental
- Price
- IBRX $2.87
- PENN $17.05
- Analyst Decision
- IBRX Strong Buy
- PENN Buy
- Analyst Count
- IBRX 5
- PENN 19
- Target Price
- IBRX $11.40
- PENN $23.03
- AVG Volume (30 Days)
- IBRX 10.1M
- PENN 4.3M
- Earning Date
- IBRX 08-11-2025
- PENN 08-07-2025
- Dividend Yield
- IBRX N/A
- PENN N/A
- EPS Growth
- IBRX N/A
- PENN N/A
- EPS
- IBRX N/A
- PENN N/A
- Revenue
- IBRX $31,222,000.00
- PENN $6,643,700,000.00
- Revenue This Year
- IBRX $567.98
- PENN $7.93
- Revenue Next Year
- IBRX $160.56
- PENN $5.59
- P/E Ratio
- IBRX N/A
- PENN N/A
- Revenue Growth
- IBRX 10238.41
- PENN 5.51
- 52 Week Low
- IBRX $1.83
- PENN $13.25
- 52 Week High
- IBRX $7.63
- PENN $23.08
- Technical
- Relative Strength Index (RSI)
- IBRX 49.40
- PENN 60.16
- Support Level
- IBRX $2.77
- PENN $15.58
- Resistance Level
- IBRX $3.24
- PENN $16.77
- Average True Range (ATR)
- IBRX 0.23
- PENN 0.62
- MACD
- IBRX -0.03
- PENN 0.15
- Stochastic Oscillator
- IBRX 19.74
- PENN 82.68
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.